8230;advanced device technologies for the treatment of obesity. , is a clinical-stage medical-device company focused on developing non-surgical non-pharmacologic devices to induce weight loss. 5 million to continue the clinical development of the TransPyloric Shuttle. A twelve-month multicenter pivotal clinical trial designed to test the safety and effectiveness of the TransPyloric Shuttle.

Immigration, Refugees and Citizenship Canada Immigration, Réfugiés et Citoyenneté Canada.

G1 Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer. We are advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications.

For over 20 years, our active management approach and relationship based business has generated attractive returns for investors. As value-oriented investment managers, we focus on less efficient aspects of our target markets believing that this is the best way to deliver attractive risk-adjusted returns for our investors. Kensington has developed a unique vehicle for the market to provide investors with access to the best emerging Canadian hedge fund managers.